CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MidAmerica Pharmaceuticals today announced that it is bringing KOURZEQ™ (triamcinolone acetonide dental paste USP, 0.1%) - a new option for the treatment of canker sores – to market. KOURZEQ™ is an FDA approved prescription oral paste that is specially formulated to treat oral lesions such as canker sores.

2023年11月14日芝加哥（GLOBE NEWSWIRE）-MidAmerica Pharmaceuticals today宣布它正在带来KOURZEQ™ （曲安奈德牙膏USP，0.1%）-治疗溃疡疮的新选择-上市。KOURZEQ™ 是FDA批准的处方口服糊剂，专门用于治疗口腔病变，如溃疡疮。

Canker sores, also called aphthous ulcers, are shallow lesions that develop on the soft tissues inside the mouth. KOURZEQ oral paste helps heal canker sores faster by reducing inflammation and providing relief of burning and pain. KOURZEQ will be available exclusively via telehealth through a partnership between MidAmerica Pharmaceuticals and BeyondMD®.

溃疡疮也称为口疮，是在口腔内软组织上形成的浅部病变。KOURZEQ口服糊剂通过减少炎症和缓解灼痛和疼痛来帮助更快地治愈溃疡疮。KOURZEQ将通过MidAmerica Pharmaceuticals和BeyondMD®之间的合作关系独家通过远程医疗提供。

Consumers simply visit kourzeq.doctalkgo.com and set up a virtual visit with a credentialed healthcare professional who can assess the patient and prescribe KOURZEQ if appropriate; the prescription can then be ordered for delivery directly to their doorstep. 'We are pleased to be offering a new FDA-approved option for those living with, and suffering from, canker sores,” said Eve del Rio, MD, Chief Medical Officer for MidAmerica Pharmaceuticals.

消费者只需访问kourzeq.doctalkgo.com，并与获得认证的医疗保健专业人员进行虚拟访问，该专业人员可以评估患者并在适当时开出kourzeq处方；然后可以订购处方直接送到他们的门口MidAmerica Pharmaceuticals首席医疗官Eve del Rio博士说，我们很高兴为患有溃疡病并患有溃疡病的人提供一种新的FDA批准的选择。

“As a board-certified dermatologist, I see how much canker sores negatively impact the daily activities of those suffering from them. We are proud to offer quick access to KOURZEQ for appropriate patients, and we are confident that it will make a positive difference for those suffering from canker sores.” 'After seeing firsthand how painful canker sores can be,” said Linda Brennan, Chief Executive Officer of MidAmerica Pharmaceuticals, “I created MidAmerica Pharmaceuticals so that we can bring a solution to millions of people.

“作为一名获得董事会认证的皮肤科医生，我看到多少溃疡疮会对患有这些疾病的人的日常活动产生负面影响。我们很自豪为适当的患者提供快速访问KOURZEQ的机会，我们相信这将对那些患者产生积极的影响。“琳达·布伦南（Linda Brennan）说，MidAmerica Pharmaceuticals的首席执行官，“我创建了MidAmerica Pharmaceuticals，以便我们为数百万人提供解决方案。

Our telehealth distribution model enables sufferers to gain quick access to a healthcare provider and KOURZ.

我们的远程医疗分发模式使患者能够快速访问医疗保健提供者和KOURZ。